Generation of VSV Pseudotypes Using Recombinant ΔG-VSV for Studies on Virus Entry, Identification of Entry Inhibitors, and Immune Responses to Vaccines

Overview

Journal J Virol Methods

Specialty Microbiology

Date 2010 Aug 17

PMID 20709108

Citations 251

Authors

Michael A Whitt

Affiliations

Soon will be listed here.

Abstract

Vesicular stomatitis virus (VSV) is a prototypic enveloped animal virus that has been used extensively to study virus entry, replication and assembly due to its broad host range and robust replication properties in a wide variety of mammalian and insect cells. Studies on VSV assembly led to the creation of a recombinant VSV in which the glycoprotein (G) gene was deleted. This recombinant (rVSV-ΔG) has been used to produce VSV pseudotypes containing the envelope glycoproteins of heterologous viruses, including viruses that require high-level biocontainment; however, because the infectivity of rVSV-ΔG pseudotypes is restricted to a single round of replication the analysis can be performed using biosafety level 2 (BSL-2) containment. As such, rVSV-ΔG pseudotypes have facilitated the analysis of virus entry for numerous viral pathogens without the need for specialized containment facilities. The pseudotypes also provide a robust platform to screen libraries for entry inhibitors and to evaluate the neutralizing antibody responses following vaccination. This manuscript describes methods to produce and titer rVSV-ΔG pseudotypes. Procedures to generate rVSV-ΔG stocks and to quantify virus infectivity are also described. These protocols should allow any laboratory knowledgeable in general virological and cell culture techniques to produce successfully replication-restricted rVSV-ΔG pseudotypes for subsequent analysis.

Citing Articles

ACE2 utilization of HKU25 clade MERS-related coronaviruses with broad geographic distribution.

Liu C, Park Y, Ma C, Stuart C, Gen R, Sun Y bioRxiv. 2025; .

PMID: 40027745 PMC: 11870458. DOI: 10.1101/2025.02.19.639017.

Recombinant VSVs: A Promising Tool for Virotherapy.

Vorona K, Moroz V, Gasanov N, Karabelsky A Acta Naturae. 2025; 16(4):4-14.

PMID: 39877014 PMC: 11771844. DOI: 10.32607/actanaturae.27501.

Intranasally administrated fusion-inhibitory lipopeptides block SARS-CoV-2 infection in mice and enable long-term protective immunity.

Mougari S, Favede V, Predella C, Reynard O, Durand S, Mazelier M Commun Biol. 2025; 8(1):57.

PMID: 39814955 PMC: 11735783. DOI: 10.1038/s42003-025-07491-4.

Swine RNF5 positively regulates the antiviral activity of IFITM1 by mediating the degradation of ABHD16A.

Shi X, Shen L, Chen S, Liu M, Wang J, Wen X J Virol. 2024; 99(1):e0127724.

PMID: 39601593 PMC: 11784460. DOI: 10.1128/jvi.01277-24.

Design of customized coronavirus receptors.

Liu P, Huang M, Guo H, McCallum M, Si J, Chen Y Nature. 2024; 635(8040):978-986.

PMID: 39478224 DOI: 10.1038/s41586-024-08121-5.

References

Klas S, Robison C, Whitt M, Miller M . Adjuvanticity of an IL-12 fusion protein expressed by recombinant deltaG-vesicular stomatitis virus. Cell Immunol. 2002; 218(1-2):59-73. DOI: 10.1016/s0008-8749(02)00575-0. View

Tatsuo H, Ono N, Tanaka K, Yanagi Y . SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000; 406(6798):893-7. DOI: 10.1038/35022579. View

Ge J, Wen Z, Wang X, Hu S, Liu Y, Kong X . Generating vesicular stomatitis virus pseudotype bearing the severe acute respiratory syndrome coronavirus spike envelope glycoprotein for rapid and safe neutralization test or cell-entry assay. Ann N Y Acad Sci. 2006; 1081:246-8. PMC: 7167956. DOI: 10.1196/annals.1373.030. View

Porotto M, Carta P, Deng Y, Kellogg G, Whitt M, Lu M . Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J Virol. 2007; 81(19):10567-74. PMC: 2045485. DOI: 10.1128/JVI.01181-07. View

Fredericksen B, Whitt M . Vesicular stomatitis virus glycoprotein mutations that affect membrane fusion activity and abolish virus infectivity. J Virol. 1995; 69(3):1435-43. PMC: 188730. DOI: 10.1128/JVI.69.3.1435-1443.1995. View

Fukushi S, Mizutani T, Saijo M, Matsuyama S, Miyajima N, Taguchi F . Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol. 2005; 86(Pt 8):2269-2274. DOI: 10.1099/vir.0.80955-0. View

Glende J, Schwegmann-Wessels C, Al-Falah M, Pfefferle S, Qu X, Deng H . Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology. 2008; 381(2):215-21. PMC: 7103374. DOI: 10.1016/j.virol.2008.08.026. View

Kaimori A, Kanto T, Limn C, Komoda Y, Oki C, Inoue M . Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. Virology. 2004; 324(1):74-83. DOI: 10.1016/j.virol.2004.03.038. View

Symons J, Alcami A, Smith G . Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell. 1995; 81(4):551-60. DOI: 10.1016/0092-8674(95)90076-4. View

10.

Kaariainen L, Gomatos P . A kinetic analysis of the synthesis in BHK 21 cells of RNAs specific for Semliki Forest virus. J Gen Virol. 1969; 5(2):251-65. DOI: 10.1099/0022-1317-5-2-251. View

11.

Tamura K, Oue A, Tanaka A, Shimizu N, Takagi H, Kato N . Efficient formation of vesicular stomatitis virus pseudotypes bearing the native forms of hepatitis C virus envelope proteins detected after sonication. Microbes Infect. 2005; 7(1):29-40. DOI: 10.1016/j.micinf.2004.09.006. View

12.

Weiss R, Boettiger D, Murphy H . Pseudotypes of avian sarcoma viruses with the envelope properties of vesicular stomatitis virus. Virology. 1977; 76(2):808-25. DOI: 10.1016/0042-6822(77)90261-6. View

13.

Zavada J, ROSENBERGOVA M . Phenotypic mixing of vesicular stomatitis virus with fowl plague virus. Acta Virol. 1972; 16(2):103-14. View

14.

Fuerst T, Niles E, Studier F, Moss B . Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 1986; 83(21):8122-6. PMC: 386879. DOI: 10.1073/pnas.83.21.8122. View

15.

Tatsuo H, Okuma K, Tanaka K, Ono N, Minagawa H, Takade A . Virus entry is a major determinant of cell tropism of Edmonston and wild-type strains of measles virus as revealed by vesicular stomatitis virus pseudotypes bearing their envelope proteins. J Virol. 2001; 74(9):4139-45. PMC: 111928. DOI: 10.1128/jvi.74.9.4139-4145.2000. View

16.

Fukushi S, Watanabe R, Taguchi F . Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins. Methods Mol Biol. 2008; 454:331-8. PMC: 7120752. DOI: 10.1007/978-1-59745-181-9_23. View

17.

Niwa H, Yamamura K, Miyazaki J . Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991; 108(2):193-9. DOI: 10.1016/0378-1119(91)90434-d. View

18.

Saha M, Tanaka A, Jinno-Oue A, Shimizu N, Tamura K, Shinagawa M . Formation of vesicular stomatitis virus pseudotypes bearing surface proteins of hepatitis B virus. J Virol. 2005; 79(19):12566-74. PMC: 1211511. DOI: 10.1128/JVI.79.19.12566-12574.2005. View

19.

Perez M, Watanabe M, Whitt M, de la Torre J . N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry. J Virol. 2001; 75(15):7078-85. PMC: 114436. DOI: 10.1128/JVI.75.15.7078-7085.2001. View

20.

Ito H, Watanabe S, Sanchez A, Whitt M, Kawaoka Y . Mutational analysis of the putative fusion domain of Ebola virus glycoprotein. J Virol. 1999; 73(10):8907-12. PMC: 112919. DOI: 10.1128/JVI.73.10.8907-8912.1999. View